Skip to Content
Merck

MAB10009

Anti-IDO Antibody, clone 1F8.2

clone 1F8.2, from mouse

Synonym(s):

Indoleamine-pyrrole 2,3-dioxygenase, indole 2,3-dioxygenase, indoleamine 2,3-dioxygenase 1, indoleamine-pyrrole 2,3 dioxygenase, IDO1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
1F8.2, monoclonal
Application:
IHC, WB
Citations:
14
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified antibody

antibody product type

primary antibodies

clone

1F8.2, monoclonal

species reactivity

human

technique(s)

immunohistochemistry: suitable, western blot: suitable

isotype

IgG1κ

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

human ... IDO1(3620)

General description

Approx. 45 kDa
Indoleamine 2,3-dioxygenase (IDO) is an enzyme that is responsible for converting tryptophan to kynurenines. IDO is expressed by a wide variety of tissues and IDO can be upregulated by interferon gamma. IDO modulates levels of the amino acid tryptophan, which is vital for cell growth, but is also involved in the suppression of the immune response. IDO may be involved in the
suppression of the immune response to tumours and blocking the IDO pathway may be a potential target for immunotherapy.

Immunogen

GST-tagged recombinant protein of full-length human IDO.

Application

Anti-IDO Antibody, clone 1F8.2 is an antibody against IDO for use in WB, IH.
Research Category
Neuroscience
Research Sub Category
Oxidative Stress

Biochem/physiol Actions

This antibody recognizes IDO.

Physical form

Format: Purified
Mouse monoclonal in buffer containing 0.1 M Tris-glycine, pH 7.4, 150 mM NaCl and 0.05% sodium azide.
Protein G Purified

Preparation Note

Maintain refrigerated at 2-8°C for 1 year from date of receipt.

Analysis Note

Control
HeLa cell lysate treated with interferon gamma.
Evaluated by Western Blot in HeLa cell lysate.
Western Blot Analysis: 0.1 µg/mL dilution of this antibody detected IDO on 15 µg of HeLa cell lysate.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

Try our Product Selector Tool to narrow your options


Storage Class

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Tamara Vorobjova et al.
World journal of gastroenterology, 21(2), 439-452 (2015-01-17)
To investigate the densities of dendritic cells (DCs) and FOXP3(+) regulatory T cells (Tregs) and their interrelations in the small bowel mucosa in untreated celiac disease (CD) patients with and without type 1 diabetes (T1D). Seventy-four patients (45 female, 29
Asha M Rudjord-Levann et al.
iScience, 26(7), 106984-106984 (2023-08-03)
Galectins are a group of carbohydrate-binding proteins with a presumed immunomodulatory role and an elusive function on antigen-presenting cells. Here we analyzed the expression of galectin-1 and found upregulation of galectin-1 in the extracellular matrix across multiple tumors. Performing an
Lieke L van der Woude et al.
Journal for immunotherapy of cancer, 10(10) (2022-10-18)
Immunotherapy is currently part of the standard of care for patients with advanced-stage non-small cell lung cancer (NSCLC). However, many patients do not respond to this treatment, therefore combination strategies are being explored to increase clinical benefit. The PEMBRO-RT trial



Global Trade Item Number

SKUGTIN
MAB1000904053252667589